1. FDA/CDER, guidance for industry, investigators, and reviewers: exploratory IND studies;Biotechnol. Law Rep.,2006
2. European Medicines Agency, ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals;ICH Guid.,2009
3. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans – a practical guide;Burt;Expert Opin. Drug Deliv.,2016
4. European Medicines Agency, Gemcitabine. Summary of Product Characteristics,2017
5. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2’,2’-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry;Vainchtein;Rapid Commun. Mass Spectrom.,2007